D. Merkel

发表

Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales.

D. Cella, J. Lai, D. Eton, 2002, Journal of pain and symptom management.

Pregnancy and breast cancer.

D. Merkel, 1996, Seminars in surgical oncology.

Primary factor in declining breast cancer mortality rates: early detection or adjuvant therapy?

D. Merkel, B. Cady, S. Sener, 2002, Cancer practice.

Promotion of self-management for post treatment cancer survivors: evaluation of a risk-adapted visit

D. Merkel, T. Hensing, J. Obel, 2016, Journal of Cancer Survivorship.

P-glycoprotein in breast cancer.

W. McGuire, S. Fuqua, D. Merkel, 1989, Cancer treatment and research.

Phase II trial of oral etoposide plus cisplatin in extensive stage small cell carcinoma of the lung: an Eastern Cooperative Oncology Group study.

D. Ettinger, W. Gradishar, D. Merkel, 1994, European journal of cancer.

Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations.

D. Merkel, C. Jackisch, R. Coleman, 2008, Cancer treatment reviews.

Laboratory aspects of multidrug resistance.

W. McGuire, S. Fuqua, D. Merkel, 1989, Cancer treatment and research.

Central nervous system toxicity with fludarabine.

D. Merkel, D. V. Von Hoff, N. L. Griffin, 1986, Cancer treatment reports.

A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer

M. Ratain, D. Merkel, R. Nanda, 2016, SpringerPlus.

Prognostic implications of ploidy and proliferative activity in diffuse large cell lymphomas.

J. Winter, W. Hauck, D. Merkel, 1986, Cancer research.

Ploidy, proliferative activity and prognosis. DNA flow cytometry of solid tumors

W. McGuire, D. Merkel, 1990, Cancer.

Electrophoretic analysis of 248 clinical breast cancer specimens for P-glycoprotein overexpression or gene amplification.

W. McGuire, S. Fuqua, D. Merkel, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study.

Robert M Elashoff, Alan Kristal, Bette Caan, 2007, Journal of the National Cancer Institute.

Flow cytometry, cellular DNA content, and prognosis in human malignancy.

W. McGuire, D. Merkel, L. Dressler, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial.

Yu Shyr, William J. Gradishar, G. Sledge, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors in breast cancer.

D. Merkel, M. McKay, A. Langlands, 1992, The New England journal of medicine.

Dna flow cytometry and pathologic grading as prognostic guides in axillary lymph node‐negative breast cancer

A. Rademaker, D. Merkel, D. Winchester, 1993, Cancer.

Adjuvant treatment of node-negative breast cancer.

D. Merkel, C. K. Osborne, 1989, Texas medicine.

erbB-2 (HER-2) and Breast Cancer Progression

D. Merkel, A. Thor, D. Moore, 2003, Applied immunohistochemistry & molecular morphology : AIMM.

Oncogenes and cancer prognosis.

W. McGuire, D. Merkel, 1988, Important advances in oncology.

Hormone Receptors and Risk in Breast Cancer

W. McGuire, D. Merkel, S. Hill, 1989 .

The importance of DNA flow cytometry in node-negative breast cancer.

A. Rademaker, D. Merkel, D. Winchester, 1990, Archives of surgery.

Priority symptoms in advanced breast cancer: development and initial validation of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16).

J. V. Von Roenn, J. Beaumont, D. Cella, 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015

G. Rosner, O. Olopade, M. Dolan, 2020, Breast Cancer Research and Treatment.

8 Steroid Receptors in Relation to Response

D. Merkel, C. K. Osborne, 1988 .

Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic

D. Merkel, G. Carro, W. Hui, 2012, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Prognostic factors in breast cancer.

W. McGuire, C. Osborne, D. Merkel, 1989, Hematology/oncology clinics of North America.